Cancer Survivor, Obesity, Overweight, Prostate Adenocarcinoma, Stage A Prostate Cancer, Stage B Prostate Cancer, Stage C Prostate Cancer, Stage D Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage III Prostate Cancer, Stage II Prostate Cancer, Stage I Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage IV Prostate Cancer
Conditions
Brief summary
This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nutrition and exercise advice for prostate cancer patients on androgen deprivation therapy may help to reduce obese frailty and change the levels of myokines in blood.
Detailed description
PRIMARY OBJECTIVES: I. Assess the effect of individualized nutrition and exercise counseling interventions on myokine expression and body composition in prostate cancer (PrCa) patients being treated with androgen deprivation therapy (ADT). SECONDARY OBJECTIVES: I. Determine any changes in muscle strength, respiratory muscle strength and functional capacity resulting from the nutrition and exercise counseling interventions. II. Determine any changes in myokines, circulating inflammatory and frailty-associated cytokines resulting from the nutrition and exercise counseling interventions. III. Determine the effect of the study interventions on dietary intake, physical activity, fatigue, and quality of life. EXPLORATORY OBJECTIVES: I. Correlate changes in secondary objectives with prostate specific antigen (PSA) and testosterone levels. II. Evaluate adherence to nutrition and exercise advice. III. Evaluate assessment tools and recruiting strategies. OUTLINE: Patients receive an individualized diet plan for 6 months. Patients complete an individualized home-based exercise program aerobic and resistance exercise over 10-30 minutes per day, at minimum 3 days per week for 6 months, and a progressive resistance exercise program including an individually tailored prescription targeting the chest, shoulders, arms, and leg musculature for 1-4 sets of 10-15 repetitions, 5 days per week over 6 months. Patients also attend monthly educational meetings for 6 months.
Interventions
DIETARY_SUPPLEMENTDietary Intervention
Receive diet plan
OTHEREducational Intervention
Attend educational meeting
BEHAVIORALExercise Intervention
Complete exercise program
OTHERQuality-of-Life Assessment
Ancillary studies
OTHERSurvey Administration
Ancillary studies
Sponsors
Roswell Park Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Biopsy-confirmed prostate adenocarcinoma of any stage/grade * Prescribed or already receiving continuous ADT for \< 5 years * Hemoglobin \> 11 g/dL * Creatinine \< 1.5 x upper limit of normal (ULN), AST or ALT \<2 x ULN within 6 months prior to enrollment * Liver function tests \< 2 x ULN * Able to walk unassisted at least 100 meters (200 steps) or ECOG \<= 1 * No contraindications to any aspect of participation, including aerobic exercise * Participant must be able to read, write, and understand the English language and be able to provide written consent * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion criteria
* Known clinically significant severe chronic obstructive pulmonary disease (COPD), ischemic heart disease, congestive heart failure, and/or significant cardiac arrhythmias * Limiting orthopedic, musculoskeletal or psychological conditions (clinician discretion) * Overall medical frailty (clinician discretion) * Any condition contraindicating additional blood collection beyond standard of care * Unwilling or unable to follow protocol requirements * Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study intervention
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in body composition | Baseline up to 6 months | Will be measured by dual X-ray absorptiometry (DXA) total body and regional lean mass, fat mass and % body fat. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in muscle strength | Baseline up to 6 months | Will be assessed by chest press, leg press, grip strength,6-minute walk test, timed-up-and-go, agility, Berg balance scale, short physical performance battery (SPPB). |
| Changes in functional capacity muscle strength | Baseline up to 6 months | Improvement of muscle strenght |
| Change in body composition | Baseline up to 6 months | All subjects will undergo dual-energy X-ray absorptiometry (DEXA) for measurements of body composition |
| myokines concentration | Baseline up to 6 months | Will be assessed by serum biomarker levels. |
| cytokines concentration | Baseline up to 6 months | Will be assessed by serum biomarker levels. |
| Health related quality of life Short Form | Up to 6 months | Will be used to assess quality of life . The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100, Lower scores = more disability, higher scores = less disability |
| Changes in dietary intake | Baseline up to 6 months | Will be assessed by National Cancer Institute Automated Self-Administered 24-hour survey. |
| Changes in physical activity | Baseline up to 6 months | Will be assessed by Godin Leisure Time survey and Fitbit activity report. Will be summarized by time point using the observed sample size, mean, and standard deviation. Will be evaluated using a two-sided permutation paired t-test. Additionally, the mean change in each outcome will be estimated using a 95% confidence interval. As exploratory analyses, the association between the change in each outcome and demographic/clinical factors may be evaluated using general linear models. The change in outcome will be modeled as a function of baseline levels and each demographic/clinical factor in a one-at-a-time manner. |
| Change in fatigue | Baseline up to 6 months | Will be assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue survey. |
| Change in Respiratory Muscle Strength | Baseline up to 6 months | Mouth pressure device |
Countries
United States
Contacts
CONTACTEllis Levine, MD
PRINCIPAL_INVESTIGATOREllis Levine, MD
Roswell Park Cancer Institute
Outcome results
None listed